
Campioni gratuiti in farmacia: sentenza Ue dice no alla fornitura di etici. Sì agli OTC

Call Me - +39 3381508675 - E-Mail: info@cyberpharmaexcellence.com

"The exchange of information between Pharma companies in the industry"




The sheer complexity involved in producing active pharmaceutical ingredients (APIs) means that up until now, the industry has relied for the most part on the traditional method of batch manufacturing. This step-by-step process which requires the completion of each batch before moving on to the next is not very time-efficient and often requires the use of numerous pieces of machinery.


Biotech accuses VGXI of blocking roll-out by refusing to facilitate tech transfer to third-party manufacturersBiotech firm Inovio Pharmaceuticals has launched a lawsuit against its partner VGXI, claiming the contract development and manufacturing organisation breached their supply agreement by refusing to provide the necessary technology transfer materials to other third-party manufacturers to produce COVID-19 vaccine candidate, INO-4800.











Although the industry might be 30% along its sustainability journey, greater interoperability is needed from materials to devices.
In an in-depth review of the market and having evaluated the collective developments from this year’s Pharmapack event, Gregor Anderson, MD of Pharmacentric Solutions, offers a positive appraisal of pharma’s drive towards sustainability, as well as identifying areas requiring further improvement.

ROMA, 13 MAG - Continua ad ampliarsi il numero di sperimentazioni cliniche sui farmaci per il trattamento del Covid-19. Due nuovi studi clinici, entrambi coordinati dall'Irccs Ospedale San Raffaele di Milano, sono stati approvati dall'Agenzia Italiana del Farmaco (Aifa). Il primo (PreCov) è uno studio controllato, randomizzato, che si propone di valutare gli effetti della somministrazione di idrossiclorochina per prevenire l'infezione da Covid-19 negli operatori sanitari a rischio. Il secondo (Combat-19) è uno studio di fase 2, multicentrico, randomizzato, che si propone di valutare, nei soggetti con polmonite causata da Covid, la sicurezza e l'efficacia rispetto al placebo di mavrilimumab. Quest'ultimo è un anticorpo monoclonale diretto contro la subunità alfa del recettore per il fattore stimolante le colonie granulocitarie-macrofagiche (GM-CSF) non ancora autorizzato, ma in corso di studio per il trattamento dell'artrite reumatoide.
https://www.federfarma.it/Edicola/Ansa-Salute-News/VisualizzaNews.aspx?type=Ansa&key=29616





The ongoing pandemic has fuelled debate about whether Western pharmaceutical supply chains and API sourcing are too dependent on lower-cost Asian suppliers such as China. Do the US and Europe need to bring manufacturing back home?COVID-19 has rekindled debate about pharmaceutical supply chains and prompted renewed calls for drug companies to source more active pharmaceutical ingredients (APIs) from the US and Europe.
Biotech in discussions with pharmaceutical and chemical manufacturers on how to broaden supply of antiviral that last week received an emergency use authorization for treatment of COVID-19 from the FDAGilead Sciences is in discussions with pharmaceutical and chemical manufacturers around the world about expanding global production and supply of its antiviral remdesivir, which has shown promise as a treatment for COVID-19, the biotech firm said on Tuesday.
